Ph.D., Senior Vice President, Products and Services R&D, Genomic Health
Ellen joined Genomic Health in 2013 and has focused on the application of next generation technologies, including sequencing and liquid-based biopsy, and software development to discover, develop and deliver Genomic Health’s next generation of products to serve patients living with cancer. In 2017, Ellen was recognized for her leadership in biotechnology and named one of the Most Influential Women in Business by San Francisco Business Times. She received a Ph.D. in Molecular Genetics and Cell Biology from The University of Chicago. Prior to joining Genomic Health, Ellen held positions of increasing responsibility at the Stanford Human Genome Center, Celera Genomics, Celera Diagnostics, Perlegen Sciences and Life Technologies.
Clinical Dx Showase: Genomic Health
Genomic Health, Inc. is the world’s leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today.
Improving OncotypeDx™ Access From Ordering To Reporting
Clinical Diagnostics testing has three customers: physicians, patients and payers. Ensuring that time to result delivery and out-of-pocket expenses are both minimized requires that all three constituents are well served. Changes to the OncotypeDX™ Invasive Breast cancer test report and ordering process that improve accessibility will be presented.